What does current research show about the efficacy, dosing, safety, and clinical applications of Lactobacillus plantarum PS128?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Research on Lactobacillus plantarum PS128

PS128 shows preliminary promise in neuropsychiatric conditions, particularly Parkinson's disease and autism spectrum disorder, but lacks robust placebo-controlled evidence for most applications and should be considered investigational rather than standard therapy.

Key Clinical Applications with Evidence

Parkinson's Disease (Strongest Signal)

PS128 demonstrated motor improvement in an open-label pilot study of 25 PD patients taking 60 billion CFU nightly for 12 weeks 1. The study showed:

  • Significant improvement in UPDRS motor scores in both OFF state (p=0.004) and ON state (p=0.007)
  • Increased ON period duration and decreased OFF period duration
  • Improved quality of life (PDQ-39 scores)
  • 68% of patients reported improvement on Patient Global Impression of Change
  • Reduced plasma myeloperoxidase and urine creatinine levels

Critical caveat: This was an open-label, single-arm study without placebo control, which substantially limits the strength of conclusions given the known placebo response in PD trials.

Animal data supports these findings, showing PS128 ameliorates motor deficits in rotenone-induced PD mice through modulation of gut microbiota and the miR-155-5p/SOCS1 inflammatory pathway 2.

Autism Spectrum Disorder

A real-world observational study of 131 autistic children and adolescents found PS128 produced greater improvements with fewer side effects compared to other probiotics 3. Effects were more pronounced in younger children. However, this was not a controlled trial and used subjective CGI ratings.

Major Depressive Disorder (Conflicting Evidence)

The evidence is contradictory:

  • An 8-week open trial in 11 MDD patients showed significant decreases in HAMD-17 and DSSS scores 4
  • However, a subsequent double-blind, placebo-controlled trial in 32 MDD patients found no significant difference between PS128 and placebo on depression severity, inflammatory markers, or gut microbiota composition 5

The placebo-controlled study supersedes the open trial, indicating PS128 likely has no clinically meaningful effect on depression beyond placebo.

Anxiety Disorders

One study of 200 anxiety patients reported PS128 combined with citalopram improved HAMA and SAS scores more than citalopram alone, with lower adverse reaction rates (4% vs 22%) 6. However, methodological details are limited and this requires replication.

Exercise Recovery

PS128 supplementation (4 weeks) prevented decreases in muscle strength (MVIC), median power frequency, and neuromuscular efficiency after a half-marathon in 8 recreational runners compared to placebo 7. This represents one of the few placebo-controlled studies showing benefit.

Dosing

The consistent dose across studies is 60 billion CFU (6 × 10^10) once daily, typically taken at night. Duration ranges from 4-12 weeks depending on indication.

Safety Profile

PS128 appears well-tolerated with minimal adverse effects reported across studies. This aligns with broader probiotic safety data showing L. plantarum strains are generally safe 8.

Important safety considerations:

  • Avoid in critically ill patients with severe immunocompromise or damaged intestinal mucosa 9
  • The general probiotic literature shows rare cases of bacterial sepsis with lactobacilli in vulnerable populations 9
  • No serious adverse events specifically attributed to PS128 in published studies

Mechanistic Considerations

PS128 is marketed as a "psychobiotic" with proposed mechanisms including:

  • Modulation of gut-brain axis signaling
  • Reduction of neuroinflammation via miR-155-5p/SOCS1 pathway 2
  • Alteration of gut microbiota composition
  • Reduction of inflammatory markers and gut permeability markers

However, the placebo-controlled MDD trial found no significant changes in inflammatory markers, gut permeability markers, or overall microbiota composition 5, questioning these mechanisms in humans.

Clinical Bottom Line

PS128 may be considered as adjunctive therapy in Parkinson's disease given the pilot data showing motor improvement, but patients must understand this is based on open-label evidence requiring confirmation in placebo-controlled trials. The 60 billion CFU nightly dose appears safe and may provide benefit with minimal downside risk.

For depression, the placebo-controlled evidence does not support use despite positive open-label findings 5.

For autism, anxiety, and exercise recovery, evidence is too preliminary to make firm recommendations, though the safety profile suggests low risk if patients wish to trial it.

The broader probiotic literature shows L. plantarum strains demonstrate the most significant effect on infection reduction in critically ill patients 8, but PS128 specifically has not been studied in this population.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.